Nom du produit:3-(difluoromethyl)-4-nitro-1H-pyrazole

IUPAC Name:3-(difluoromethyl)-4-nitro-1H-pyrazole

CAS:1789048-54-9
Formule moléculaire:C4H3F2N3O2
Pureté:95%+
Numéro de catalogue:CM416928
Poids moléculaire:163.08

Unité d'emballage Stock disponible Prix($) Quantité
CM416928-100mg in stock şşş
CM416928-250mg in stock ǠŸǺ
CM416928-10g in stock ǠŸǺǺ
CM416928-25g in stock ŸœǺǺ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1789048-54-9
Formule moléculaire:C4H3F2N3O2
Point de fusion:-
Code SMILES:[O-][N+](=O)C1=CNN=C1C(F)F
Densité:
Numéro de catalogue:CM416928
Poids moléculaire:163.08
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.

Column Infos

KT-474
Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.